Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2)

30 Oct 2012

Abstract excerpt

BACKGROUND: Enhancer of zeste homologue 2 (EZH2) is a polycomb group (PcG) family protein. Acting as a histone methyltransferase it plays crucial roles in maintaining epigenetic stem cell signature, while its deregulation leads to tumor development. EZH2 overexpression is commonly associated with poor prognosis in a variety of tumor types including carcinomas, lymphomas and soft tissue sarcomas. However, although...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Genomics and Chromatin Dynamics
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23110793
DOI: 10.1186/1479-5876-10-216

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2)PMID 23110793Read ↗

Role of EZH2 in cancer stem cells: from biological insight to a therapeutic targetSemantic proximity Read ↗

Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.Semantic proximity Read ↗

Enhancer of Zeste Homolog 2 Overexpression Has a Role in the Development of Anaplastic Thyroid CarcinomasSemantic proximity Read ↗

The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinomaSemantic proximity Read ↗

Genetic and Molecular Heterogeneity of Synovial Sarcoma and Associated Challenges in TherapySemantic proximity Read ↗

Overexpression of enhancer of zests homolog 2 in lymphoma.Semantic proximity Read ↗

EZH2-associated tumor malignancy: A prominent target for cancer treatment.Semantic proximity Read ↗

Overexpression of EZH2 is associated with clinicopathological parameters and poor prognosis in gliomasSemantic proximity Read ↗

Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasmsSemantic proximity Read ↗

Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor SurvivalSemantic proximity Read ↗

Synovial Sarcoma Chromatin Dynamics Reveal a Continuum in SS18:SSX ReprogramingSemantic proximity Read ↗

Targeting epigenetics in sarcomas through EZH2 inhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.